pioneers in
regenerative
medicine
improving patient quality of life by reducing bone infections through accessible, high-performance synthetic solutions
About osteoVate
A collaboration between the University of Sheffield and Ceramisys Ltd., we are pioneers in regenerative medicine. Our multidisciplinary team combines academic rigour with industrial expertise to solve the most pressing challenges in bone grafting procedures.
We bridge the gap between materials science and clinical application to provide surgeons with next-generation medical devices. Our mission is to improve patient quality of life by reducing bone infections through accessible, high-performance synthetic solutions that redefine the standard of care in modern bone grafting.
The Problem
Bone infections are a devastating surgical complication, causing prolonged suffering and high healthcare costs. Surgeons face a dual challenge: the need for effective regeneration and the urgent requirement to prevent bacterial colonisation.
Current injectable substitutes rely on antibiotics, which face the rising threat of antimicrobial resistance. There is an urgent, unmet clinical need for a syntheticgraft that is easy to deploy and naturally resistant to microorganisms. Our solution utilises multiple modes of antibacterial attack without conventional antibiotics, effectively lessening the risk of resistance.
Bone infections are rising
No injectable antibacterial grafts exist
Antibiotics are losing effectiveness
Our Technology
InOsteon utilises a patented, inorganic modification of nanoscale hydroxyapatite paste. By incorporating strontium and zinc oxide, the material achieves a >99.9% reduction in living bacteria and inhibits biofilm formation.
This antibiotic-free action remains non-toxic to mammalian cells, ensuring safe tissue healing. The injectable, ready-to-use device provides a scaffold mimickingnatural bone architecture. This dual-action framework—combining osteoconduction with potent antimicrobial properties—is protected by grants in 12 Europeancountries and Australia, marking a milestone in biomaterial innovation.
99.9% reductionin living bacteria
Non-toxic to mammalian cells
Inhibits biofilm formation
Promotes tissue healing
Value Proposition
InOsteon represents a paradigm shift in bone grafting, offering a dual-action solution that promotes healing while preventing infection. Our patented technology delivers potent antibacterial activity without antibiotics, mitigating the risk of antimicrobial resistance.
By enhancing hydroxyapatite with strontium and zinc oxide, InOsteon ensures superior bone integration in a ready-to-use, injectable format. We provide theorthopaedic, spinal, and dental markets with a high-efficiency device that reduces surgical complexity, lowers healthcare costs, and improves recovery outcomes for even the most vulnerable patients.
Our core team
Dr. Caroline Harrison
Entrepreneurial Lead InOsteon inventor
Future CEO with 14+ years in bone graft R&D. She leads OsteoVate’s spinout andregulatory strategy.
Prof. Cheryl Miller
Scientific Adviser
Biomedical expert with 25+ years’ experience and £12M+ in funding. Cheryl provides scientific oversight and holds three patents.
Alex Wilkinson
Tech Transfer Officer
Clinical translation lead with 20+ years’ experience. He directs commercial frameworks and global regulatory roadmaps.
Keith Jackson
Business Adviser
Former CEO of JRI Orthopaedics and specialist in MedTech scaling and international market entry.
Contact us
Get in touch with the OsteoVate team to discuss next steps or request more information.